Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator

Background: No effective approaches to target mutant Kras have yet been developed. Immunoprevention using KRAS-specific antigenic peptides to trigger T cells capable of targeting tumor cells relies heavily on lipid metabolism. To facilitate better TCR/peptide/MHC interactions that result in better Cancer preventive efficacy, we combined KVax with avasimibe, a specific ACAT1 Inhibitor, tested their anti-cancer efficacy in mouse lung Cancer models, where Kras mutation was induced before vaccination.

Methods: Control of tumor growth utilizing a multi-peptide Kras vaccine was tested in combination with avasimibe in a syngeneic lung Cancer mouse model and a genetically engineered mouse model (GEMM). Activation of immune responses after administration of Kras vaccine and avasimibe was also assessed by flow cytometry, ELISpot and IHC.

Findings: We found that Kras vaccine combined with avasimibe significantly decreased the presence of regulatory T cells in the tumor microenvironment and facilitated CD8+ T cell infiltration in tumor sites. Avasimibe also enhanced the efficacy of Kras vaccines target mutant Kras. Whereas the Kras vaccine significantly increased antigen-specific intracellular IFN-γ and granzyme B levels in CD8+ T cells, avasimibe significantly increased the number of tumor-infiltrating CD8+ T cells. Additionally, modulation of Cholesterol metabolism was found to specifically impact in T cells, and not in Cancer cells.

Interpretation: Avasimibe complements the efficacy of a multi-peptide Kras vaccine in controlling lung Cancer development and growth. This treatment regimen represents a novel immunoprevention approach to prevent lung Cancer.